Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
This episode includes insights from around the biopharma world for the business week ended 22 January 2021.
This time we have more from JPM including mid-term launch plans from a UK major and how successful the virtual format was, contingency plans for a single-dose coronavirus vaccine, an antibody for COVID-19, and a roundup of the industry’s own views of its prospects for the coming year.
Scrip Podcasts Now On Spotify!
These and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Play, SoundCloud and TuneIn - and now on Spotify Podcasts - and also via smart speakers if one of these channels has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "GSK Aims To Launch 13 Blockbusters In Five Years" - Scrip, 18 Jan, 2021.)
(Also see "J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business" - Scrip, 14 Jan, 2021.)
(Also see "J&J Has A Plan B If Gamechanger Single Dose Vaccine Disappoints" - Scrip, 15 Jan, 2021.)
(Also see "Humanigen Takes Aim At IL-6 Inhibitors With CRS Drug Lenzilumab" - Scrip, 20 Jan, 2021.)
(Also see "Scrip Asks…What Does 2021 Hold For Biopharma? Part 1: Tackling COVID-19" - Scrip, 18 Jan, 2021.)